OncLive TV

Dr. Ranee Mehra on the Importance of Symptom Management in Head and Neck Cancer

August 5th 2016

Dr. David F. McDermott on Nivolumab in RCC

August 5th 2016

Dr. Kuerer on De-Escalating Surgery in the Treatment of Patients With Breast Cancer

August 5th 2016

Henry M. Kuerer, MD, PhD, professor of Surgery, PH and Fay Etta Robinson Distinguished Professor in Research, Breast Surgical Oncology, executive director, Breast Programs, director, Breast Surgical Oncology Fellowship Training Program, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses de-escalating surgery in the treatment of patients with breast cancer.

Dr. Robert Coleman on the Importance of BRCA Testing in Ovarian Cancer

August 4th 2016

Robert Coleman, MD a professor in the Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, discusses the importance of BRCA testing for patients diagnosed with ovarian cancer.

Dr. Luke Nordquist on Radium-223 Retreatment

August 4th 2016

Luke Nordquist, MD, FACP, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses a multicenter, prospective study of radium-223 retreatment in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Yurgelun on Educating Patients on Genetic Testing for CRC

August 4th 2016

Matthew Yurgelun, MD, instructor in medicine, Harvard Medical School, Dana-Farber Cancer Institute, explains why oncologists should discuss genetic testing with their patients and family members for colorectal cancer, as well as some of the common risk factors for the disease.

Dr. Rodriguez on Systemic Therapy in Salivary Gland Cancer

August 4th 2016

Cristina P. Rodriguez, MD, hematology oncologist, University of Washington School of Medicine in Seattle, discusses the emerging role of systemic therapy for patients with salivary gland cancer.

Dr. Yardley on Unmet Need for Patients With HER2+ Breast Cancer

August 3rd 2016

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the unmet need for patients with HER2-positive breast cancer.

Dr. Fischkoff on Vision for TIL Therapy in Melanoma

August 3rd 2016

Steven A. Fischkoff, MD, chief medical officer of Lion Biotechnologies, Inc, discusses his vision for tumor-infiltrating lymphocyte therapy for patients with melanoma.

Dr. Keith T. Flaherty on 3-Year Follow-up of COMBI-d in Metastatic Melanoma

August 2nd 2016

Dr. Peter O'Donnell on Atezolizumab and IMvigor 210

August 2nd 2016

Dr. Nir Peled on Next-Generation Sequencing in Lung Cancer

August 2nd 2016

Gyorgy Petrovics on Frequency of BRCA Mutations in African American Prostate Cancer Patients

August 2nd 2016

Gyorgy Petrovics, PhD, associate director, Center for Prostate Disease Research (CPDR), research associate professor in the department of surgery at the Uniformed Services University of the Health Sciences (USUHS), discusses BRCA1 and BRCA2 mutations in African American prostate cancer patients.

Challenges With a Precision Medicine-Based Approach in Oncology

August 1st 2016

Holli Dilks, PhD, director, Personalized Medicine Operations, Sarah Cannon Research Institute, discusses the challenges associated with having a precision medicine-based approach in the field of oncology.

Dr. Topalian on Evolution of PD-1/PD-L1 Agents in Oncology

August 1st 2016

Suzanne L. Topalian, MD, director, Melanoma Program, professor of Surgery, Johns Hopkins Medicine, discusses how the use of PD-1/PD-L1 inhibitors in multiple tumor types has dramatically evolved over the last 4 years.

Dr. Holmes Discusses Late Recurrence and the MA.17R Trial in Breast Cancer

July 30th 2016

Dr. Bellon on Ongoing Trials in Omitting Radiation in Breast Cancer Treatment

July 29th 2016

Jennifer Bellon, MD, radiation oncologist, Dana-Farber Cancer Institute, discusses some of the current ongoing trials looking at omitting radiation when it comes to the treatment of patients with breast cancer.

Dr. Falchook on KTN3379 in Advanced Tumors

July 29th 2016

Gerald S. Falchook, MD, director, Drug Development, Sarah Cannon Research Institute, discusses a phase Ib study examining the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of the anti-ErbB3 agent KTN3379 in adults with advanced tumors. The agent was studied alone and with targeted therapies.

Dr. El-Jawahri on Early Integrated Palliative Care in Patients With Lung or GI Cancer

July 29th 2016

Areej R. El-Jawahri, MD, assistant in Medicine, Massachusetts General Hospital, instructor in Medicine, Harvard Medical School, discusses a study examining early integrated palliative care for patients with gastrointestinal (GI) or lung cancer and the impact it has on family caregiver outcomes.

Martin Moorhead on Role of Minimal Residual Disease in Leukemia and Lymphoma

July 29th 2016